{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-022403","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.939306+00:00","generated_at":"2026-05-31T22:36:56.821915+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Monopar enrolls first patient in Phase 1 trial of MNPR-101-Zr radiopharmaceutical","bullets":["First-in-human Phase 1 dosimetry and imaging trial of MNPR-101-Zr, a uPAR-targeting radiopharmaceutical.","Up to 12 patients with advanced cancers will be enrolled in the study.","Trial led by Professor Rodney Hicks at the Melbourne Theranostic Innovation Centre.","First human study of a radiolabeled monoclonal antibody targeting uPAR."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-022403","json":"https://secwatch.observer/filing/0001437749-24-022403.json","markdown":"https://secwatch.observer/filing/0001437749-24-022403.md","text":"https://secwatch.observer/filing/0001437749-24-022403.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924022403/0001437749-24-022403-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924022403/mnpr20240708_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:36:56.821915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}